June Lee
CIK 1696493 · EVP, Chief Development Officer · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$11.7K
Companies
4
Total Filings
28
Lifetime Open-Market Net
-$1.36M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TNYA | Director | — | $0.76 | — | $0 | 6 | 2026-05-29 |
| ELDN | Director | 3,430 | $3.40 | $11.7K | $0 | 5 | 2026-01-16 |
| CinCor Pharma, Inc. (CINC) Delisted | Director | — | $29.06 | — | $0 | 2 | 2023-02-24 |
| MyoKardia, Inc. (MYOK) Delisted | EVP, Chief Development Officer | 18,793 | — | — | -$1.36M | 15 | 2019-10-29 |
Recent Filings · Page 2 of 3
28 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-02 | ELDN | Grant (A) | — | $0 | EDGAR |
| 2022-01-10 | CinCor Pharma, Inc. (CINC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-22 | TNYA | Grant (A) | — | $0 | EDGAR |
| 2019-10-29 | MyoKardia, Inc. (MYOK) Delisted | Exer (M) | +18,004 | $215.1K | EDGAR |
| 2019-09-24 | MyoKardia, Inc. (MYOK) Delisted | Mixed | −426 | -$625.9K | EDGAR |
| 2019-09-20 | MyoKardia, Inc. (MYOK) Delisted | Mixed | — | -$245.3K | EDGAR |
| 2019-08-12 | MyoKardia, Inc. (MYOK) Delisted | Mixed | — | -$205.7K | EDGAR |
| 2019-06-03 | MyoKardia, Inc. (MYOK) Delisted | Grant (A) | +401 | $16.4K | EDGAR |
| 2019-03-18 | MyoKardia, Inc. (MYOK) Delisted | Exer (M) | +1,758 | $21.0K | EDGAR |
| 2019-02-12 | MyoKardia, Inc. (MYOK) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.